Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular function and remodelling
Open Access
- 9 May 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 103 (4), 498-508
- https://doi.org/10.1093/cvr/cvu125
Abstract
We previously demonstrated that pharmacological activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) protects the heart against acute ischaemia/reperfusion injury. Here, we determined the benefits of chronic activation of ALDH2 on the progression of heart failure (HF) using a post-myocardial infarction model. We showed that a 6-week treatment of myocardial infarction-induced HF rats with a selective ALDH2 activator (Alda-1), starting 4 weeks after myocardial infarction at a time when ventricular remodelling and cardiac dysfunction were present, improved cardiomyocyte shortening, cardiac function, left ventricular compliance and diastolic function under basal conditions, and after isoproterenol stimulation. Importantly, sustained Alda-1 treatment showed no toxicity and promoted a cardiac anti-remodelling effect by suppressing myocardial hypertrophy and fibrosis. Moreover, accumulation of 4-hydroxynonenal (4-HNE)-protein adducts and protein carbonyls seen in HF was not observed in Alda-1-treated rats, suggesting that increasing the activity of ALDH2 contributes to the reduction of aldehydic load in failing hearts. ALDH2 activation was associated with improved mitochondrial function, including elevated mitochondrial respiratory control ratios and reduced H2O2 release. Importantly, selective ALDH2 activation decreased mitochondrial Ca2+-induced permeability transition and cytochrome c release in failing hearts. Further supporting a mitochondrial mechanism for ALDH2, Alda-1 treatment preserved mitochondrial function upon in vitro aldehydic load. Selective activation of mitochondrial ALDH2 is sufficient to improve the HF outcome by reducing the toxic effects of aldehydic overload on mitochondrial bioenergetics and reactive oxygen species generation, suggesting that ALDH2 activators, such as Alda-1, have a potential therapeutic value for treating HF patients.This publication has 39 references indexed in Scilit:
- Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophyJournal of Molecular and Cellular Cardiology, 2011
- Aldehyde dehydrogenase 2 knockout accentuates ethanol-induced cardiac depression: Role of protein phosphatasesJournal of Molecular and Cellular Cardiology, 2010
- Regulation of mitochondrial processes: A target for heart failureDrug Discovery Today: Disease Mechanisms, 2010
- Mitochondrial aldehyde dehydrogenase and cardiac diseasesCardiovascular Research, 2010
- Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKCɛ) knockout miceJournal of Molecular and Cellular Cardiology, 2010
- Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variantNature Structural & Molecular Biology, 2010
- Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenalBiochemical Journal, 2009
- Ischaemic preconditioning improves proteasomal activity and increases the degradation of PKC during reperfusionCardiovascular Research, 2009
- Aldehyde Dehydrogenase 2 in Cardiac Protection: A New Therapeutic Target?Trends in Cardiovascular Medicine, 2009
- Myocardial ischaemia inhibits mitochondrial metabolism of 4-hydroxy-trans-2-nonenalBiochemical Journal, 2008